Download PDF
Nervenheilkunde 2007; 26(01/02): 74-78
DOI: 10.1055/s-0038-1626835
Original- und Übersichtsarbeiten - Original and Review Articles
Schattauer GmbH

Myotone Dystrophien – Phänotypen, Pathogenese, Diagnostik und Therapie

Zusammenfassung eines Minisymposiums im Rahmen der Neurowoche 2006, MannheimMyotonic dystrophies – phenotypes, pathogenesis, diagnostics and therapyProceedings of a symposium at the German Neurowoche 2006, Mannheim, Germany
B. G. H. Schoser
1   Neurologische Klinik, Ludwig-Maximilians-Universität München (Leitender Arzt: Prof. Dr. D. Pongratz)
› Author Affiliations
Further Information

Publication History

Publication Date:
19 January 2018 (online)

    Permissions and Reprints

Zusammenfassung

Zwei Formen der myotonen Dystrophie (DM1, DM2) sind bisher beschrieben. 1992 konnte als genetische Ursache der DM1 ein abnorm expandiertes CTG-Triplettrepeat im 3´-UTR (untranslated region) des Dystrophia myotonica Proteinkinasegens (DMPK) auf Chromosom 19 gefunden werden. Die DM2 wurde 1994 durch Ricker und Thornton beschrieben und 2001 konnte ein abnorm expandiertes Tetranukleotid CCTG-Repeat im Intron 1 des Zinkfinger-9-Gens (ZNF-9) auf Chromosom 3q als kausal identifiziert werden. Multisystemische Symptome betreffen Skelettmuskulatur, Gehirn, Auge, Herz und Endokrinum. Der heterogenen Ätiologie mit zwei genetischen Loci liegt pathogenetisch eine RNA-Prozessierungsstörung mit alternativem Spleißen von organspezifischen Genen zugrunde (sogenanntes Konzept der Spleißeopathie).

Unser Symposium umfasste Beiträge zu aktuellen Aspekten der Klinik, Diagnostik, Bildgebung, Geburtshilfe und Schwangerschaft, molekularen RNA-Pathogenese sowie symptomatischen und molekularen Therapieoptionen.

Summary

Myotonic dystrophies cover at least two clinical and molecular distinct forms, the classic (Steinert’s disease; DM1) and the new type (Ricker’s disease, DM2). In 1992, the mutation causing DM1 was identified as a CTG repeat in the DMPK gene on chromosome 19q, and in 2001 the mutation causing DM2 was identified as a CCTG repeat in the ZNF-9 gene on chromosome 3q. The pathogenesis of both forms seems to be based ona gain-of-function RNA mechanism, as multisystemic features are caused by alternative splicing of tissue specific genes. Thus, recently the term spliceopathy was introduced. Our symposium focused on multisystemic clinical features, new diagnostic techniques, new aspects of the molecular pathogenesis and symptomatic treatment options.

Schlüsselwörter

DM1 - DM2 - myotone Dystrophien - Repeat-Erkrankung - Therapie

Keywords

DM1 - DM2 - myotonic dystrophy - repeat disorder - treatment
 

  • Literatur

  • 1 Bachinski LL. et al. Confirmation of DM2 (CCTG)n expansion mutation in PROMM/PDM patients of different European origins: a single shared haplotype indicates ancestral founder effects. Am J Hum Genet 2003; 73: 835-48.
    CrossrefPubMedGoogle Scholar
  • 2 Bhakta D, Lowe MR, Groh WJ. Prevalence of structural cardiac abnormalities in patients with myotonic dystrophy type I. Am Heart J 2004; 147: 224-47.
    CrossrefPubMedGoogle Scholar
  • 3 Brook JD. et al. Molecular basis of myotonic dystrophy: expansion of a trinucleotide (CTG) repeat at the 3’ end of a transcript encoding a protein kinase family member. Cell 1992; 68: 799-808.
    CrossrefPubMedGoogle Scholar
  • 4 Cho DH, Tapscott SJ. Myotonic dystrophy: Emerging mechanisms for DM1 and DM2. Biochim Biophys Acta. 2006 PMID: 16876389.
    PubMedGoogle Scholar
  • 5 Gaul C. et al. Subtle cognitive dysfunction in adult myotonic dystrophy type 1 (DM1) and type 2 (DM2). Neurology 2006; 67: 350-2.
    CrossrefPubMedGoogle Scholar
  • 6 George A. et al. Musculoskeletal pain as the most prominent feature in myotonic dystrophy type 2 Schmerz. 2006 PMID: 16758212.
    PubMedGoogle Scholar
  • 7 George A. et al. Musculoskeletal pain in patients with myotonic dystrophy type 2. Arch Neurol 2004; 61: 1938-42.
    PubMedGoogle Scholar
  • 8 Gomes-Pereira M, Monckton DG. Chemical modifiers of unstable expanded simple sequence repeats: what goes up, could come down. Mutat Res 2006; 598: 15-34.
    CrossrefPubMedGoogle Scholar
  • 9 Harper PS. Myotonic Dystrophy. 3rd edition. London: W. B. Sauders; 2001
    Google Scholar
  • 10 Jakubiczka S. et al. A strategy for reliable diagnosis of PROMM/DM2. Neurogenetics 2004; 05: 55-9.
    CrossrefPubMedGoogle Scholar
  • 11 Kanadia RN. et al. Reversal of RNA missplicing and myotonia after muscleblind overexpression in a mouse poly(CUG) model for myotonic dystrophy. Proc Natl Acad Sci USA 2006; 103: 11748-53.
    CrossrefPubMedGoogle Scholar
  • 12 Kassubek J. et al. Quantification of brain atrophy in patients with myotonic dystrophy and proximal myotonic myopathy: a controlled 3-dimensional magnetic resonance imaging study. Neurosci Lett 2003; 348: 73-6.
    CrossrefPubMedGoogle Scholar
  • 13 Kornblum C. et al. Distinct neuromuscular phenotypes in myotonic dystrophy types 1 and 2: a whole body highfield MRI study. J Neurol 2006; 253: 753-61.
    CrossrefPubMedGoogle Scholar
  • 14 Kornblum C. et al. Cranial magnetic resonance imaging in genetically proven myotonic dystrophy type 1 and 2. J Neurol 2004; 251: 710-4.
    PubMedGoogle Scholar
  • 15 Langlois MA. et al. Cytoplasmic and nuclear retained DMPK mRNAs are targets for RNA interference in myotonic dystrophy cells. J Biol Chem 2005; 280: 16949-54.
    CrossrefPubMedGoogle Scholar
  • 16 Leroy O. et al. ETR-3 represses Tau exons 2/3 inclusion, a splicing event abnormally enhanced in myotonic dystrophy type I. J Neurosci Res 2006; 84: 852-9.
    CrossrefPubMedGoogle Scholar
  • 17 Liquori CL. et al. Myotonic dystrophy type 2 caused by a CCTG expansion in intron 1 of ZNF9. Science 2001; 293: 864-7.
    CrossrefPubMedGoogle Scholar
  • 18 Liquori CL. et al. Myotonic Dystrophy Type 2: Human founder haplotype and evolutionary conservation of the repeat tract. Am J Hum Genet 2003; 73: 849-62.
    CrossrefPubMedGoogle Scholar
  • 19 Mahadevan M. et al. Myotonic dystrophy mutation: an unstable CTG repeat in the 3’ untranslated region of the gene. Science 1992; 255: 1253-5.
    CrossrefPubMedGoogle Scholar
  • 20 Mahadevan MS. et al. Reversible model of RNA toxicity and cardiac conduction defects in myotonic dystrophy. Nat Genet 2006; 38: 1066-70.
    CrossrefPubMedGoogle Scholar
  • 21 Margolis JM. et al. DM2 intronic expansions: evidence for CCUG accumulation without flanking sequence or effects on ZNF9 mRNA processing or protein expression. Hum Mol Genet 2006; 15: 1808-15.
    CrossrefPubMedGoogle Scholar
  • 22 Maurage CA. et al. Similar brain tau pathology in DM2/PROMM and DM1/Steinert disease. Neurology 2005; 65: 1636-8.
    CrossrefPubMedGoogle Scholar
  • 23 Osborne RJ, Thornton CA. RNA-dominant diseases. Hum Mol Genet 2006; 15: 162-9.
    CrossrefPubMedGoogle Scholar
  • 24 Ota M. et al. Relationship between diffusion tensor imaging and brain morphology in patients with myotonic dystrophy. Neurosci Lett 2006; 407: 234-9.
    CrossrefPubMedGoogle Scholar
  • 25 Ranum LP, Cooper TA. RNA-mediated neuromuscular disorders. Annu Rev Neurosci 2006; 29: 259-77.
    CrossrefPubMedGoogle Scholar
  • 26 Rudnik-Schoneborn S. et al. Outcome and effect of pregnancy in myotonic dystrophy type 2. Neurology 2006; 66: 579-80.
    CrossrefPubMedGoogle Scholar
  • 27 Ricker K. et al. Proximal myotonic myopathy: a new dominant disorder with myotonia, muscle weakness, and cataracts. Neurology 1994; 44: 1448-52.
    CrossrefPubMedGoogle Scholar
  • 28 Schara U, Schoser BG. Myotonic dystrophies type 1 and 2: a summary on current aspects. Semin Pediatr Neurol 2006; 13: 71-9.
    CrossrefPubMedGoogle Scholar
  • 29 Schneider-Gold C. et al. Cardiac and skeletal muscle involvement in myotonic dystrophy type 2 (DM2): a quantitative 31P-MRS and MRI study. Muscle Nerve 2004; 30: 636-44.
    CrossrefPubMedGoogle Scholar
  • 30 Schoser BG. Myotone Dystrophien – Aktueller Stand der molekularen Pathogenese. Akt Neurol 2005; 32: 324-30.
    Article in Thieme ConnectGoogle Scholar
  • 31 Schoser BG. et al. Sudden cardiac death in myotonic dystrophy type 2. Neurology 2004; 63: 2402-4.
    CrossrefPubMedGoogle Scholar
  • 32 Sergeant N. et al. Dysregulation of human brain microtubule-associated tau mRNA maturation in myotonic dystrophy type 1. Hum Mol Genet 2001; 10: 2143-55.
    CrossrefPubMedGoogle Scholar
  • 33 Thornton CA, Griggs RC, Moxley RT. 3rd edition Myotonic dystrophy with no trinucleotide repeat expansion. Ann Neurol 1994; 35: 269-72.
    CrossrefPubMedGoogle Scholar
  • 34 Timchenko NA. et al. RNA CUG repeats sequester CUGBP1 and alter protein levels and activity of CUGBP1. J Biol Chem 2001; 276: 7820-6.
    CrossrefPubMedGoogle Scholar
  • 35 Timchenko L. Reversal of fortune. Nat Genet 2006; 38: 976-7.
    CrossrefPubMedGoogle Scholar
  • 36 Udd B. et al. Report of the 115th ENMC workshop: DM2/PROMM and other myotonic dystrophies. 3rd Workshop, 14–16 February 2003, Naarden, The Netherlands. Neuromuscl Disord 2003; 13: 589-96.
    Google Scholar
  • 37 Udd B. et al. 140th ENMC International Workshop: Myotonic Dystrophy DM2/PROMM and other myotonic dystrophies with guidelines on management. Neuromuscul Disord 2006; 16: 403-13.
    CrossrefPubMedGoogle Scholar
  • 38 Vielhaber S. et al. Brain 1H magnetic resonance spectroscopic differences in myotonic dystrophy type 2 and type 1. Muscle Nerve 2006; 34: 145-52.
    CrossrefPubMedGoogle Scholar